E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of meningococcal infection |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027274 |
E.1.2 | Term | Meningococcal infection |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10046859 |
E.1.2 | Term | Vaccination |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of the study is to describe the number of polysaccharide and carrier protein specific antibody secreting cells identified in the tonsils following immunisation with the quadrivalent meningococcal conjugate vaccine
|
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives include describing the number of polysaccharide and carrier protein specific memory B-cells in the tonsils following immunisation with the quadrivalent meningococcal conjugate vaccine and the immunophenotype of these cells.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Written informed consent for the study to be performed according to the study schedule. • Adults 18-45 years scheduled to undergo routine tonsillectomy. • Availability for all the visits scheduled in the study. • Ability to understand the written information provided.
|
|
E.4 | Principal exclusion criteria |
- Tonsillectomy for allergic conditions - Tonsil required for histopathological or other examination - Receipt of any vaccination, or investigational agent, within 90 days of enrolment to the study or the expectation of receiving any investigational agent or any vaccines prior to the day planned for SBA blood draw (Day 28+7days). Exception for group 4 for whom the expectation of receiving any investigational agent or any vaccines is not allowed until tonsillectomy (Day 42 +/-3 days). Influenza vaccine may be administered up to 15 days prior to study vaccination and no less than 15 days after study vaccination - Receipt of immunosuppressive therapy within the 30 days prior to enrolment (systemic or inhaled corticosteroids administered for more than 5 days, or any cancer chemotherapy, during any of the 30 days prior to enrolment). Topical steroids will be allowed. - A history of meningococcal infection or close contact with a proven index case within the previous 60 days - Pregnancy or plans to become pregnant during study - Breast feeding - Any chronic cardiac, respiratory, gastrointestinal, renal, neurological or psychiatric condition or a history of drug or alcohol dependence. - Any confirmed or suspected immunodeficiency (congenitial or acquired) - Administration of immunoglobulins or any other blood products within one year of study enrolment or planned administration during the study period - Receipt of immunostimulant medication - Donation of blood products within two months of study enrolment or plan to donate blood products within two months of study completion - History of anaphylactic shock or an allergic reaction to a previous vaccination or to any vaccine component. - Acute infectious illness or fever (oral temperature > 38.0°C) during the three days preceding study enrolment. - Significant acute infections requiring systemic antibiotic treatment within the past 14 days - Lack of availability for any planned visit during the study period - Bleeding diathesis, or any condition that may be associated with a prolonged bleeding time; - Known cytogenic disorders - Any condition which, in the opinion of the clinical research team, in discussion with the chief investigator, may interfere with the evaluation of the study objectives for any reason. - Any previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s) with the exception of meningococcal serogroup C conjugate vaccines
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint for the study is the number of polysaccharide and carrier protein specific antibody secreting cells identified in the tonsils following immunisation with the quadrivalent meningococcal conjugate vaccine |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Status prior to vaccination |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last visit of the last subject undergoing the trial defines the end of the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |